Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2010

View Archived Issues

Pharmacological profile supports evaluation of GSK-1427400 in chronic pain

INNOVATE-PCI trial data support entry of antiplatelet agent elinogrel in phase III trial

Intranasal desmopressin ineffective in relieving renal colic pain

Scientists identify susceptibility locus for HBV-related hepatocellular carcinoma

Bayer Schering claims new hepatocyte growth factor receptor inhibitors

Regeneron provides update on trials of aflibercept in metastatic colorectal cancer

New histamine H4 receptor ligand VUF-11488 to be tested in inflammation models

Positive outcome of decentralized procedure for Faes Farma's bilastine in Europe

Abbott discloses new CANP 1 inhibitors

Enanta Pharmaceuticals claims new antibacterial agents

Merck Frosst Canada presents new acyl-CoA desaturase inhibitors

Shire and Acceleron sign exclusive license agreement for ACTR-IIB molecules

Vanderbilt University claims new allosteric acetylcholine M1 receptor agonists

Anchor Therapeutics and Ortho-McNeil-Janssen to codevelop GPCR-targeted drugs

Daiichi Sankyo's laninamivir is approved for influenza treatment in Japan

Mymetics' HIV vaccine to enter preclinical study in primates

Marshall Edwards to acquire Novogen's isoflavone-related intellectual property

SciMeDent completes acquisition of DiabetRX

Bristol-Myers Squibb initiates tender offer to acquire ZymoGenetics

Debiopharm and Aurigene nominate Debio-0617 as development candidate

FDA approves new 500-mg dose of Faslodex

Phase I data presented on VGX-3100 in HPV-linked cervical dysplasia and cancer

RedHill Biopharma completes transactions for drugs in late-stage clinical development

Genmab reports phase II data on ofatumumab in multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...